References
- Steinberg W. The clinical utility of the CA 19-9 tumorassociated antigen. Am J Gastroenterol 1990;85:350-5.
- Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol 1999;10 Suppl 4:145-9. https://doi.org/10.1023/A:1008386130283
- Pearce S, Thornes H, Carr D, Tanner A. Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction. Gut 1994;35:707-8. https://doi.org/10.1136/gut.35.5.707
- Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S10-9. https://doi.org/10.1016/j.ijrobp.2009.07.1754
- National Cancer Institute, Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [Internet]. Bethesda, MD: National Cancer Institute; c2016 [cited 2016 Jun 7]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
- Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26:474-9. https://doi.org/10.1053/ejso.1999.0925
- Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem 1998;35(Pt 1):99-103. https://doi.org/10.1177/000456329803500113
- Pines E, Slama JL, Holeman A, Ley G, Malbec D, Boudon P. Unusually high level of CA 19-9 in chronic pancreatitis. Gastroenterol Clin Biol 1995;19:641-2.
- Safi F, Roscher R, Beger HG. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma. Bull Cancer 1990;77:83-91.
- Petit JM, Vaillant G, Olsson NO, et al. Elevated serum CA19-9 levels in poorly controlled diabetic patients: relationship with Lewis blood group. Gastroenterol Clin Biol 1994;18:17-20.
- Kodama T, Satoh H, Ishikawa H, Ohtsuka M. Serum levels of CA19-9 in patients with nonmalignant respiratory diseases. J Clin Lab Anal 2007;21:103-6. https://doi.org/10.1002/jcla.20136
- Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 2001;59:237-45. https://doi.org/10.1016/S0167-8140(01)00328-0
- Azria D, Magne N, Zouhair A, et al. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 2005;31:555-70. https://doi.org/10.1016/j.ctrv.2005.07.008
- Friedlander PA, Bansal R, Schwartz L, Wagman R, Posner J, Kemeny N. Gemcitabine-related radiation recall preferentially involves internal tissue and organs. Cancer 2004;100:1793-9. https://doi.org/10.1002/cncr.20229
- Jeter MD, Janne PA, Brooks S, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002;53:394-400. https://doi.org/10.1016/S0360-3016(02)02773-6
- Ganem G, Solal-Celigny P, Joffroy A, Tassy D, Delpon A, Dupuis O. Radiation myositis: the possible role of gemcitabine. Ann Oncol 2000;11:1615-6. https://doi.org/10.1023/A:1008353224251
- O'Regan KN, Nishino M, Armand P, Kelly PJ, Hwang DG, Di Salvo D. Sonographic features of pectoralis muscle necrosis secondary to gemcitabine-induced radiation recall: case report and review of current literature. J Ultrasound Med 2010;29:1499-502. https://doi.org/10.7863/jum.2010.29.10.1499
- Matthews RH, Kadoch C, Ercal N. Alcohol as a potential contributing factor in radiation complications. Clin Adv Hematol Oncol 2009;7:257-62.
- Reed GB Jr, Cox AJ Jr. The human liver after radiation injury: a form of veno-occlusive disease. Am J Pathol. 1966;48:597-611.
- Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27. https://doi.org/10.1200/JCO.2006.08.2644